A prospective, randomized study to compare the combination of imatinib and cytarabine versus imatinib alone in newly diagnosed patients with chronic phase chronic myeloid leukemia

CONCLUSION: Imatinib with low-dose ara-c can be considered as a potential first-line treatment option for CML-CP.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research